Obinutuzumab Promotes Renal Preservation in Lupus Nephritis

A post hoc analysis of the NOBILITY trial showed improved outcomes for patients taking obinutuzumab (Gazyva) compared with placebo.
Medscape Medical News

source https://www.medscape.com/viewarticle/998310?src=rss